Britain and America have concluded a major trade agreement that will ensure zero import taxes on British pharmaceutical products entering the American market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has committed to increase spending on pharmaceuticals through the National Health Service (NHS). This commitment guarantees that tariffs on these crucial goods will be held at nothing for a period of the next three years.
This deal comes after previous threats to hike tariffs on patented pharmaceutical imports, with figures floated up to double the cost.
"This agreement between the United Kingdom bolsters the worldwide climate for new treatments and introduces much-needed fairness to U.S.–U.K. drug exports," an announcement noted.
Commercial Significance
Pharmaceuticals constitute one of the Britain's most significant goods shipped to the America, which is easily the largest market for large British pharmaceutical firms.
Statistics reveal that in the 12 months leading up to last September, the UK shipped pharmaceutical products worth over eleven billion pounds to the US. This value accounted for 17.4% of all goods exports in that period.
"This agreement secures work, boosts investment and facilitates the UK to become a international leader for biotech and pharma," the Business and Trade Secretary commented.
Key NHS Changes
The agreement includes several specific pledges from the United Kingdom:
- Price Threshold Increase: The UK will increase the affordability limit at which it judges new treatments to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a goal to increase overall public funding on drugs from 0.3% of the national economy to 0.6 percent over the next decade.
- Rebate Cap: The amount manufacturers must pay back to the NHS to stay within budget will be restricted at fifteen percent. Last year, rebates exceeded twenty percent.
Recent Tensions
This agreement comes amid a ongoing dispute between the pharmaceutical industry and the ministers over spending levels and regulatory access.
The disagreement were exacerbated by arguments that US consumers were paying several times more for the equivalent treatments than patients in the other developed nations.
Over the last 18 months, several significant drug company projects in the UK have been halted or abandoned, while major expansions have been directed toward American operations.
One official publicly accepted that the NHS had to spend more on medicines, noting that its budget allocation on drugs had decreased as a share of its total funding over the previous ten-year period.
